PMID- 32278976
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20221207
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 170
DP  - 2020 Jun 15
TI  - NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in 
      mice.
PG  - 108029
LID - S0028-3908(20)30095-2 [pii]
LID - 10.1016/j.neuropharm.2020.108029 [doi]
AB  - Migraine is an extraordinarily prevalent and disabling headache disorder that 
      affects one billion people worldwide. Throbbing pain is one of several migraine 
      symptoms including sensitivity to light (photophobia), sometimes to sounds, smell 
      and touch. The basic mechanisms underlying migraine remain inadequately 
      understood, and current treatments (with triptans being the primary standard of 
      care) are not well tolerated by some patients. NOP (Nociceptin OPioid) receptors, 
      the fourth member of the opioid receptor family, are expressed in the brain and 
      periphery with particularly high expression known to be in trigeminal ganglia 
      (TG). The aim of our study was to further explore the involvement of the NOP 
      receptor system in migraine. To this end, we used immunohistochemistry to examine 
      NOP receptor distribution in TG and trigeminal nucleus caudalus (TNC) in mice, 
      including colocalization with specific cellular markers, and used nitroglycerin 
      (NTG) models of migraine to assess the influence of the selective NOP receptor 
      agonist, Ro 64-6198, on NTG-induced pain (sensitivity of paw and head using von 
      Frey filaments) and photophobia in mice. Our immunohistochemical studies with 
      NOP-eGFP knock-in mice indicate that NOP receptors are on the majority of neurons 
      in the TG and are also very highly expressed in the TNC. In addition, Ro 64-6198 
      can dose dependently block NTG-induced paw and head allodynia, an effect that is 
      blocked by the NOP antagonist, SB-612111. Moreover, Ro 64-6198, can decrease 
      NTG-induced light sensitivity in mice. These results suggest that NOP receptor 
      agonists should be futher explored as treatment for migraine symptoms. This 
      article is part of the special issue on Neuropeptides.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Targowska-Duda, Katarzyna M
AU  - Targowska-Duda KM
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL, 
      United States; Department of Biopharmacy, Medical University of Lublin, Lublin, 
      Poland.
FAU - Ozawa, Akihiko
AU  - Ozawa A
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL, 
      United States.
FAU - Bertels, Zachariah
AU  - Bertels Z
AD  - Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, United 
      States.
FAU - Cippitelli, Andrea
AU  - Cippitelli A
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL, 
      United States.
FAU - Marcus, Jason L
AU  - Marcus JL
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL, 
      United States.
FAU - Mielke-Maday, Hanna K
AU  - Mielke-Maday HK
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL, 
      United States.
FAU - Zribi, Gilles
AU  - Zribi G
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL, 
      United States.
FAU - Rainey, Amanda N
AU  - Rainey AN
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL, 
      United States.
FAU - Kieffer, Brigitte L
AU  - Kieffer BL
AD  - Douglas Hospital Research Center, Dep. of Psychiatry, School of Medicine, McGill 
      University, Montreal, Quebec, Canada; INSERM U1114, Strasbourg, France.
FAU - Pradhan, Amynah A
AU  - Pradhan AA
AD  - Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, United 
      States.
FAU - Toll, Lawrence
AU  - Toll L
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL, 
      United States. Electronic address: ltoll@health.fau.edu.
LA  - eng
GR  - R01 DA023281/DA/NIDA NIH HHS/United States
GR  - R01 DA040688/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200306
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Imidazoles)
RN  - 0 (Receptors, Opioid)
RN  - 0 (Ro 64-6198)
RN  - 0 (Spiro Compounds)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - 0 (Nociceptin Receptor)
RN  - 0 (Oprl1 protein, mouse)
SB  - IM
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Imidazoles/pharmacology/*therapeutic use
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Migraine Disorders/*chemically induced/*drug therapy/metabolism
MH  - Nitroglycerin/*toxicity
MH  - Receptors, Opioid/*agonists/metabolism
MH  - Spiro Compounds/pharmacology/*therapeutic use
MH  - Trigeminal Nuclei/*drug effects/metabolism
MH  - Nociceptin Receptor
PMC - PMC7243257
MID - NIHMS1584917
OTO - NOTNLM
OT  - Cephalic pain
OT  - Glyceryl trinitrate
OT  - NOP receptor
OT  - Nitroglycerine
OT  - Ro 64-6198
OT  - Trigeminal ganglia
COIS- Declaration of competing interest The authors declare no conflict of interest.
EDAT- 2020/04/13 06:00
MHDA- 2021/06/04 06:00
PMCR- 2021/06/15
CRDT- 2020/04/13 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/02/11 00:00 [revised]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/04/13 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/04/13 06:00 [entrez]
PHST- 2021/06/15 00:00 [pmc-release]
AID - S0028-3908(20)30095-2 [pii]
AID - 10.1016/j.neuropharm.2020.108029 [doi]
PST - ppublish
SO  - Neuropharmacology. 2020 Jun 15;170:108029. doi: 10.1016/j.neuropharm.2020.108029. 
      Epub 2020 Mar 6.